Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients... Show more
Roivant Sciences is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines across autoimmune and cardiopulmonary diseases. Its lead programs include brepocitinib, a TYK2/JAK1 inhibitor marketed as LISRAYA for dermatomyositis and in development for non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402, an anti-FcRn antibody targeting IgG-mediated autoimmune conditions; and mosliciguat, an inhaled sGC activator for pulmonary hypertension associated with interstitial lung disease. The company also incubates discovery-stage and health-technology ventures.
Investors follow ROIV closely because of its cash-rich balance sheet — roughly $4.2 billion in cash, cash equivalents, and marketable securities — and a catalyst-dense pipeline spanning multiple late-stage clinical readouts and regulatory milestones.
Over the trailing 30 days, ROIV advanced approximately 17.6%, moving from a closing price of $33.62 on October 14, 2026, to $39.53 on November 13, 2026. The stock bottomed near $33 in early October before rallying sharply through late October and early November as positive clinical and financial updates reached the market.
The broader three-month trend was more moderate but still positive, with shares up roughly 9% from a $36.28 close on August 13, 2026. That quarterly move masks significant volatility: the stock spiked in early September, pulled back into mid-October, and then reaccelerated on the strength of recent data releases.
The primary catalyst was Roivant's fiscal second-quarter 2027 report, released on November 9, 2026. The company posted a GAAP loss per share of $0.27, beating consensus, while revenue of $35.1 million came in well above the roughly $3.7 million analysts expected. The revenue beat was led by LISRAYA, which generated $31 million in net product revenue in its first five weeks following FDA approval in August 2026.
Clinical news also fueled the advance. Roivant reported that IMVT-1402 met the primary endpoint in the randomized-withdrawal period of its trial in difficult-to-treat rheumatoid arthritis, with 92.5% of patients on the 600 mg dose maintaining an ACR20 response versus 75.6% on placebo. Separately, mosliciguat delivered encouraging results in pulmonary hypertension with interstitial lung disease, including a 56% CBO-adjusted reduction in pulmonary vascular resistance and a 35-meter improvement in six-minute walk distance.
These developments prompted analyst action. Citi maintained a Buy rating with a $56 price target in late October, and H.C. Wainwright reiterated a Buy rating with a $47 target following the earnings report. The consensus analyst rating remained Strong Buy.
The trailing quarter was shaped by Roivant's transition into a commercial-stage business. The August 2026 FDA approval and launch of LISRAYA in dermatomyositis marked the company's entry into marketed products and provided investors with a tangible revenue stream for the first time.
That commercial milestone was accompanied by a steady cadence of clinical updates, including positive mosliciguat data in PH-ILD, Phase 3 brepocitinib results in non-infectious uveitis, and the IMVT-1402 rheumatoid arthritis readouts. A strong balance sheet and ongoing share repurchases — roughly $280 million in the first half of the fiscal year — lent additional support. The quarter was not without setbacks, however: Roivant noted it did not succeed in chronic cutaneous lupus erythematosus and is unlikely to advance IMVT-1402 in Sjögren's disease, factors that tempered some of the rally.
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots from a broader platform that offers hundreds of automated strategies across thousands of tickers. Only the top-performing and most relevant bots are featured in this section, helping traders filter through a large universe of algorithmic approaches. The bots vary widely in strategy, holding timeframe, and performance metrics, so investors can compare options aligned with different risk profiles and objectives. For those interested in supplementing fundamental analysis with systematic, data-driven tools, exploring the Trending AI Robots section can provide additional perspective on how automated strategies approach stocks like ROIV.
Looking ahead, investors are likely to monitor several key catalysts. The regulatory path for IMVT-1402 in rheumatoid arthritis remains a focal point, with management still in discussions with the FDA over Phase 3 trial design and endpoints. Commercial execution of LISRAYA will also be closely watched, including payer coverage dynamics and prescription growth beyond the initial launch.
Additional pipeline updates could shape sentiment, including a supplemental New Drug Application for brepocitinib in non-infectious uveitis expected in the first half of calendar 2027, the ongoing Phase 3 mosliciguat program, and upcoming Graves' disease and myasthenia gravis data from Immunovant. Broader biotech sentiment and interest-rate conditions may also influence the stock. These factors present both opportunity and execution risk, and none of this information should be interpreted as investment advice.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The Moving Average Convergence Divergence (MACD) for ROIV turned positive on October 21, 2026. Looking at past instances where ROIV's MACD turned positive, the stock continued to rise in 47 of 57 cases over the following month. The odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on ROIV as a result. In 74 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
ROIV moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ROIV crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
Following a +2.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where ROIV advanced for three days, in 230 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 187 of 241 cases where ROIV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
The 10-day RSI Indicator for ROIV moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 31 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 84%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 57 cases where ROIV's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ROIV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
ROIV broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.637) is normal, around the industry mean (3.586). ROIV has a moderately low P/E Ratio (-108.000) as compared to the industry average of (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. ROIV's P/S Ratio (3333.333) is slightly higher than the industry average of (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 7 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. ROIV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 64 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology